An article written by Seb Murray using his specific business-friendly and concise style about Cyntegrity and its founders:
“The evolution of clinical trials, with increases in globalization, study complexity and technological capabilities, means there is a need to bring innovative approaches to drug development. Artem Andrianov, a Cass Business School MBA, is making that a reality.
The Frankfurt-based venture is poised to benefit from regulatory changes, which will facilitate innovation in clinical trials, including risk-based monitoring and the use of technological tools to ensure robust oversight and reporting. New regulation to usher in these changes was endorsed by the Steering Committee of the ICH, the global umbrella of regulatory authorities, last year.”